Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.36 |
| ▸ | F9 | P00740 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | PROC | P04070 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10198641 | 0.94 | F10 (0.46) | F10MTNR1AMTNR1BF9NOS1 | |
| SCHEMBL10260041 | 0.90 | F10 (0.43) | F10F9NOS1PLGPROC | |
| SCHEMBL13429567 | 0.87 | F10 (0.41) | F10F9NOS1PLGPROC | |
| SCHEMBL15275016 | 0.81 | F10 (0.43) | F10MTNR1AMTNR1BSMN1; SMN2NOS1 | |
| SCHEMBL16603461 | 0.81 | F10 (0.42) | F10MTNR1AMTNR1BNOS1 | |
| SCHEMBL16603511 | 0.80 | F10 (0.41) | F10MTNR1AMTNR1BNOS1PLG | |
| SCHEMBL16603473 | 0.79 | F10 (0.38) | F10MTNR1AMTNR1BNOS1 | |
| SCHEMBL16169747 | 0.78 | F10 (0.40) | F10MTNR1AMTNR1B | |
| SCHEMBL16169694 | 0.78 | F9 (0.34) | F10MTNR1AMTNR1BF9L3MBTL1 | |
| SCHEMBL16169705 | 0.76 | F9 (0.32) | F10MTNR1AMTNR1BF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20160287586-A1 | COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS INFECTIONS | CELLCEUTIX CORPORATION | 2016-10-06 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | F10 2584/4885MTNR1A 49/4885MTNR1B 79/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | F10 2361/4885MTNR1A 129/4885MTNR1B 275/4885 |
| US-20160287586-A1 | COMPOUNDS AND METHODS FOR TREATING CANDIDIASIS AND ASPERGILLUS INFECTIONS | ERG28, DPM1, MANBA | F10 3405/4885MTNR1A 1526/4885MTNR1B 1982/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | F10 4834/4885MTNR1A 652/4885MTNR1B 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.